Cargando…
CEST theranostics: label-free MR imaging of anticancer drugs
Image-guided drug delivery is of great clinical interest. Here, we explored a direct way, namely CEST theranostics, to detect diamagnetic anticancer drugs simply through their inherent Chemical Exchange Saturation Transfer (CEST) MRI signal, and demonstrated its application in image-guided drug deli...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872720/ https://www.ncbi.nlm.nih.gov/pubmed/26837220 http://dx.doi.org/10.18632/oncotarget.7141 |
_version_ | 1782432771949461504 |
---|---|
author | Li, Yuguo Chen, Hanwei Xu, Jiadi Yadav, Nirbhay N. Chan, Kannie W. Y. Luo, Liangping McMahon, Michael T. Vogelstein, Bert van Zijl, Peter C.M. Zhou, Shibin Liu, Guanshu |
author_facet | Li, Yuguo Chen, Hanwei Xu, Jiadi Yadav, Nirbhay N. Chan, Kannie W. Y. Luo, Liangping McMahon, Michael T. Vogelstein, Bert van Zijl, Peter C.M. Zhou, Shibin Liu, Guanshu |
author_sort | Li, Yuguo |
collection | PubMed |
description | Image-guided drug delivery is of great clinical interest. Here, we explored a direct way, namely CEST theranostics, to detect diamagnetic anticancer drugs simply through their inherent Chemical Exchange Saturation Transfer (CEST) MRI signal, and demonstrated its application in image-guided drug delivery of nanoparticulate chemotherapeutics. We first screened 22 chemotherapeutic agents and characterized the CEST properties of representative agents and natural analogs in three major categories, i.e., pyrimidine analogs, purine analogs, and antifolates, with respect to chemical structures. Utilizing the inherent CEST MRI signal of gemcitabine, a widely used anticancer drug, the tumor uptake of the i.v.-injected, drug-loaded liposomes was successfully detected in CT26 mouse tumors. Such label-free CEST MRI theranostics provides a new imaging means, potentially with an immediate clinical impact, to monitor the drug delivery in cancer. |
format | Online Article Text |
id | pubmed-4872720 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-48727202016-05-25 CEST theranostics: label-free MR imaging of anticancer drugs Li, Yuguo Chen, Hanwei Xu, Jiadi Yadav, Nirbhay N. Chan, Kannie W. Y. Luo, Liangping McMahon, Michael T. Vogelstein, Bert van Zijl, Peter C.M. Zhou, Shibin Liu, Guanshu Oncotarget Priority Research Paper Image-guided drug delivery is of great clinical interest. Here, we explored a direct way, namely CEST theranostics, to detect diamagnetic anticancer drugs simply through their inherent Chemical Exchange Saturation Transfer (CEST) MRI signal, and demonstrated its application in image-guided drug delivery of nanoparticulate chemotherapeutics. We first screened 22 chemotherapeutic agents and characterized the CEST properties of representative agents and natural analogs in three major categories, i.e., pyrimidine analogs, purine analogs, and antifolates, with respect to chemical structures. Utilizing the inherent CEST MRI signal of gemcitabine, a widely used anticancer drug, the tumor uptake of the i.v.-injected, drug-loaded liposomes was successfully detected in CT26 mouse tumors. Such label-free CEST MRI theranostics provides a new imaging means, potentially with an immediate clinical impact, to monitor the drug delivery in cancer. Impact Journals LLC 2016-02-02 /pmc/articles/PMC4872720/ /pubmed/26837220 http://dx.doi.org/10.18632/oncotarget.7141 Text en Copyright: © 2016 Li et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Priority Research Paper Li, Yuguo Chen, Hanwei Xu, Jiadi Yadav, Nirbhay N. Chan, Kannie W. Y. Luo, Liangping McMahon, Michael T. Vogelstein, Bert van Zijl, Peter C.M. Zhou, Shibin Liu, Guanshu CEST theranostics: label-free MR imaging of anticancer drugs |
title | CEST theranostics: label-free MR imaging of anticancer drugs |
title_full | CEST theranostics: label-free MR imaging of anticancer drugs |
title_fullStr | CEST theranostics: label-free MR imaging of anticancer drugs |
title_full_unstemmed | CEST theranostics: label-free MR imaging of anticancer drugs |
title_short | CEST theranostics: label-free MR imaging of anticancer drugs |
title_sort | cest theranostics: label-free mr imaging of anticancer drugs |
topic | Priority Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872720/ https://www.ncbi.nlm.nih.gov/pubmed/26837220 http://dx.doi.org/10.18632/oncotarget.7141 |
work_keys_str_mv | AT liyuguo cesttheranosticslabelfreemrimagingofanticancerdrugs AT chenhanwei cesttheranosticslabelfreemrimagingofanticancerdrugs AT xujiadi cesttheranosticslabelfreemrimagingofanticancerdrugs AT yadavnirbhayn cesttheranosticslabelfreemrimagingofanticancerdrugs AT chankanniewy cesttheranosticslabelfreemrimagingofanticancerdrugs AT luoliangping cesttheranosticslabelfreemrimagingofanticancerdrugs AT mcmahonmichaelt cesttheranosticslabelfreemrimagingofanticancerdrugs AT vogelsteinbert cesttheranosticslabelfreemrimagingofanticancerdrugs AT vanzijlpetercm cesttheranosticslabelfreemrimagingofanticancerdrugs AT zhoushibin cesttheranosticslabelfreemrimagingofanticancerdrugs AT liuguanshu cesttheranosticslabelfreemrimagingofanticancerdrugs |